Riparian

Bespoke solutions at the intersection of strategy, compliance, and operational excellence in government pricing programs and commercial contract operations.

About

Riparian, a Two Labs company logo
SSAE 18 Badge for Riparian, a Two Labs company

Visit Riparian to Learn More

Riparian Leadership

David Chan

General Manager, President, and Co-Founder of Riparian

David brings 20+ years of experience in the life sciences where he has orchestrated the efforts of numerous multidisciplinary and cross-functional teams, and assisted organizations with financial, operational, and government exposures inherent in the complex and self-reporting nature of contractual arrangements.

Cynthia Hwang

Senior Vice President and Co-Founder of Riparian

Cynthia has 20+ years of experience advising a variety of clients in the life sciences industry – including generic drug manufacturers, “traditional” brand drug manufacturers, and manufacturers of specialty therapeutics (including gene therapy). Cynthia successfully exited a previous consulting startup through a sale to IQVIA.

Managed Services

Don Russell

Vice President, Riparian Managed Services

Joseph Scott

Associate Director, Government Pricing

Tammy Meadows

Associate Director, Client Relationships

Sophie Djihanian

Associate Director, Cross-Functional & Client Onboarding

Consulting

Jennifer Lospinoso

Managing Director & Consulting Lead

Lynn Buhl, MBA

Managing Director

Susan Dunne

Managing Director

Chris Callahan

Associate Director

Michelle Scheid Meyer

Director

Technology

Luca Bernardo Ciddio

Chief Architect

Andrew Kim

Engineering Lead

What can we help you with today?

No matter where you are in the process, we’re here to support, advise, and implement key strategies to ensure the success of your product.

Medicaid Proposed Rule Reference Guide

The Centers for Medicare & Medicaid Services (“CMS”) issued a Proposed Rule on May 26, 2023 to implement policies in the Medicaid Drug Rebate Program (“MDRP”) related to the Medicaid Services Investment and Accountability Act of 2019 (“MSIAA”) (the “Proposed Rule”). This summary is meant as a reference guide as you consider the potential impact of the Proposed Rule on your organization.

Learn More >

Riparian Insights

Want to dig a little deeper into what Riparian can do for you? Here are just a few examples of how we make a difference for our clients.

We’re here to support your success from clinical to commercial – and beyond.

How can we help you today?